Cargando…
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
AIMS: In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with reduced ejection fraction. METHODS AND RESULTS: Hea...
Autores principales: | Butler, Javed, Anker, Stefan D, Filippatos, Gerasimos, Khan, Muhammad Shahzeb, Ferreira, João Pedro, Pocock, Stuart J, Giannetti, Nadia, Januzzi, James L, Piña, Ileana L, Lam, Carolyn S P, Ponikowski, Piotr, Sattar, Naveed, Verma, Subodh, Brueckmann, Martina, Jamal, Waheed, Vedin, Ola, Peil, Barbara, Zeller, Cordula, Zannad, Faiez, Packer, Milton |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014525/ https://www.ncbi.nlm.nih.gov/pubmed/33420498 http://dx.doi.org/10.1093/eurheartj/ehaa1007 |
Ejemplares similares
-
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022) -
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022) -
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial
por: Packer, Milton, et al.
Publicado: (2021) -
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022) -
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced
por: Zannad, Faiez, et al.
Publicado: (2020)